WilliamBradParkerMD

PubMed

• Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck.
  Behbahani, T. E.,Rosenthal, E. L.,Parker, W. B.,Sorscher, E. J.> ;Head Neck. 2019 Jan 12
• 6-Methylpurine derived sugar modified nucleosides: Synthesis and evaluation of their substrate activity with purine nucleoside phosphorylases.
  Hassan, A. E.,Abou-Elkhair, R. A.,Parker, W. B.,Allan, P. W.,Secrist, J. A.> ;Bioorg. Chem.. 2016 Jan 09
• Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.
  Thottassery, J. V.,Sambandam, V.,Allan, P. W.,Maddry, J. A.,Maxuitenko, Y. Y.,Tiwari, K.,Hollingshead, M.,Parker, W. B.> ;Cancer Chemother. Pharmacol.. 2014 Jun 09
• A prescription for clinical immunology: the pills are available and ready for testing. A review.
  Parker, W.,Perkins, S. E.,Harker, M.,Muehlenbein, M. P.> ;Curr Med Res Opin. 2012 May 23
• New method for improving the accuracy of bite registrations in restorative implant dentistry.
  Hernandez, M.,Pette, G. A.,Grenier, A.,Villanueva, C.,Lask, E.,Parker, W.> ;Compend Contin Educ Dent. 2012 Feb
• Identification of Rv0535 as methylthioadenosine phosphorylase from Mycobacterium tuberculosis.
  Buckoreelall, K., Sun, Y., Hobrath, J.V., Wilson, L., Parker, W.B., Cairns, N.> ;Tuberculosis (Edinb). 2012 Mar
• Isolation and characterization of a murine p388 leukemia line resistant to thiarabine.
  Waud, W.R., Parker, W.B., Gilbert, K.S., Secrist, J.A.> ;Nucleosides Nucleotides Nucleic Acids. 2012
• Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling ...
  Hassan, A.A., Abou-Elkhair, R.I., Riordan, J.M., Allan, P.W., Parker, W.B., Khare, R., Waud, W.R., Montgomery, J.A., Secrist, J.A.> ;Eur J Med Chem. 2012 Jan
• Gingival enlargement.
  Pette, G.A., Siegel, M.A., Parker, W.B.> ;J Am Dent Assoc. 2011 Nov
• Isolation and characterization of a murine p388 leukemia line resistant to clofarabine.
  Waud, W.R., Gilbert, K.S., Parker, W.B., Secrist, J.A.> ;Nucleosides Nucleotides Nucleic Acids. 2011 Nov
• Identification and characterization of two adenosine phosphorylase activities in Mycobacterium smegmatis.
  Buckoreelall, K., Wilson, L., Parker, W.B.> ;J Bacteriol. 2011 Oct
• The Crystal Structure of Streptococcus pyogenes Uridine Phosphorylase Reveals a Distinct Subfamily of Nucleoside Phosphorylases.
  Tran, T. H., Christoffersen, S., Allan, P. W., Parker, W. B., Piskur, J., Serra, I., Terreni, M., Ealick, S. E.> ;Biochemistry. 2011 Aug 2
• Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.
  Parker, W. B.,Allan, P. W.,Waud, W. R.,Hong, J. S.,Sorscher, E. J.> ;Cancer Gene Ther.. 2011 Mar 12
• Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.
  Bertino, J.R., Waud, W.R., Parker, W.B., Lubin, M.> ;Cancer Biol Ther. 2011 Apr 1
• Cryopreserved amniotic membrane for modulation of periodontal soft tissue healing: a pilot study.
  Velez, I., Parker, W.B., Siegel, M.A., Hernandez, M.> ;J Periodontol. 2010 Dec
• Treatment planning and surgical considerations in implant therapy for patients with agenesis, oligodontia, and ectodermal dysplasia: review and case presentation.
  Sclar, A.G., Kannikal, J., Ferreira, C.F., Kaltman, S.I., Parker, W.B.> ;J Oral Maxillofac Surg. 2009-11-01
• Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.
  Parker, W.B.> ;Chem Rev. 2009-07-01
• Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.
  Ungerechts, G., Springfeld, C., Frenzke, M.E., Lampe, J., Johnston, P.B., Parker, W.B., Sorscher, E.J., Cattaneo, R.> ;Cancer Res. 2007 Nov 15
• Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus.
  Chung, D., Sun, Y., Parker, W.B., Arterburn, J.B., Bartolucci, A., Jonsson, C.B.> ;J Virol. 2007 Nov
• An immunocompetent murine model for oncolysis with an armed and targeted measles virus.
  Ungerechts, G., Springfeld, C., Frenzke, M.E., Lampe, J., Parker, W.B., Sorscher, E.J., Cattaneo, R.> ;Mol Ther. 2007 Nov
• Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
  Sun, Y., Chung, D., Chu, Y., Jonsson, C.B., Parker, W.B.> ;Antimicrob Agents Chemother. 2007 Jan
• Antiangiogenic activity of 4'-thio-beta-D-arabinofuranosylcytosine.
  Roy, A.M., Tiwari, K.N., Parker, W.B., Secrist, J.A., Li, R., Qu, Z.> ;Mol Cancer Ther. 2006 Sep
• c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.
  Thottassery, J.V., Westbrook, L., Someya, H., Parker, W.B.> ;Mol Cancer Ther. 2006 Feb
• Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy.
  Bharara, S., Sorscher, E.J., Gillespie, G.Y., Lindsey, J.R., Hong, J.S., Curlee, K.V., Allan, P.W., Gadi, V.K., Alexander, S.A., Secrist, J.A., Parker, W.B., Waud, W.R.> ;Hum Gene Ther. 2005 Mar
• Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant.
  Parker, W.B., Allan, P.W., Ealick, S.E., Sorscher, E.J., Hassan, A.A., Silamkoti, A.V., Fowler, A.T., Waud, W.R., Secrist, J.A.> ;Nucleosides Nucleotides Nucleic Acids. 2005
• Join now to see all